Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas. Adding subcutaneous sasanlimab to Bacillus ...

(RTTNews) - Pfizer Inc. (PFE), on Friday, announced that its pivotal Phase 3 trial of investigational anti-PD-1 monoclonal antibody, Sasanlimab, in patients with BCG-naïve, high-risk non-muscle ...

Sasanlimab combined with BCG significantly improves event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's phase 3 results suggest sasanlimab may redefine ...

Hympavzi was discovered by the scientists at Pfizer. Credit: © 2025 Pfizer Inc. All rights reserved. · Clinical Trials Arena · © 2025 Pfizer Inc. All rights ...

Pfizer Inc. announced results from the pivotal phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus ...

Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis. First results of ...

Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research. Computational pathology to predict docetaxel benefit in ...

Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of ...

US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC).

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody ...